{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:00:19Z","timestamp":1786759219655,"version":"build-2736575974"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Commun Med"],"DOI":"10.1038\/s43856-025-01171-4","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:18:00Z","timestamp":1763641080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["APOE \u03b54 potentiates tau related reactive astrogliosis assessed by cerebrospinal fluid YKL40 in Alzheimer\u2019s disease"],"prefix":"10.1038","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5593-7717","authenticated-orcid":false,"given":"Lydia","family":"Trudel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7826-4781","authenticated-orcid":false,"given":"Joseph","family":"Therriault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur C.","family":"Macedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1306-2708","authenticated-orcid":false,"given":"Marcel S.","family":"Woo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nesrine","family":"Rahmouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9tienne","family":"Aumont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stijn","family":"Servaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7542-7541","authenticated-orcid":false,"given":"Seyyed Ali","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2183-1551","authenticated-orcid":false,"given":"Jo\u00e3o Pedro","family":"Ferrari-Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruna","family":"Bellaver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2134-9829","authenticated-orcid":false,"given":"Pamela L.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9134-5949","authenticated-orcid":false,"given":"Tevy","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9130-5461","authenticated-orcid":false,"given":"Yi-Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime","family":"Fernandez-Arias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yansheng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4578-2033","authenticated-orcid":false,"given":"Brandon","family":"Hall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Hopewell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-2062-3516","authenticated-orcid":false,"given":"Chris Hung-Hsin","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9369-0498","authenticated-orcid":false,"given":"Maxime","family":"Montembeault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Klostranec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9345-0347","authenticated-orcid":false,"given":"Yasser","family":"Iturria-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8953-1542","authenticated-orcid":false,"given":"Paolo","family":"Vitali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1422-4358","authenticated-orcid":false,"given":"Thomas K.","family":"Karikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea L.","family":"Benedet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Gauthier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9057-8014","authenticated-orcid":false,"given":"Tharick A.","family":"Pascoal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1890-4193","authenticated-orcid":false,"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9116-1376","authenticated-orcid":false,"given":"Pedro","family":"Rosa-Neto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"key":"1171_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jalz.2011.10.007","volume":"8","author":"BT Hyman","year":"2012","unstructured":"Hyman, B. T. et al. National Institute on Aging-Alzheimer\u2019s Association guidelines for the neuropathologic assessment of Alzheimer\u2019s disease. Alzheimers Dement. 8, 1\u201313 (2012).","journal-title":"Alzheimers Dement."},{"key":"1171_CR2","doi-asserted-by":"crossref","unstructured":"Jack, C. R. Jr. et al. Revised criteria for diagnosis and staging of Alzheimer\u2019s disease: Alzheimer\u2019s Association Workgroup. Alzheimers Dement. 20, 5143\u20135169 (2024).","DOI":"10.1002\/alz.13859"},{"key":"1171_CR3","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S1474-4422(15)70016-5","volume":"14","author":"MT Heneka","year":"2015","unstructured":"Heneka, M. T. et al. Neuroinflammation in Alzheimer\u2019s disease. Lancet Neurol. 14, 388\u2013405 (2015).","journal-title":"Lancet Neurol."},{"key":"1171_CR4","doi-asserted-by":"publisher","first-page":"342","DOI":"10.2174\/1871527322666230303114425","volume":"23","author":"G Ayyubova","year":"2024","unstructured":"Ayyubova, G. APOE4 is a risk factor and potential therapeutic target for Alzheimer\u2019s disease. CNS Neurol. Disord. Drug Targets 23, 342\u2013352 (2024).","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"1171_CR5","doi-asserted-by":"publisher","first-page":"89ra57","DOI":"10.1126\/scitranslmed.3002156","volume":"3","author":"JM Castellano","year":"2011","unstructured":"Castellano, J. M. et al. Human apoE isoforms differentially regulate brain amyloid-beta peptide clearance. Sci. Transl. Med. 3, 89ra57 (2011).","journal-title":"Sci. Transl. Med."},{"key":"1171_CR6","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.neuron.2017.11.013","volume":"96","author":"CC Liu","year":"2017","unstructured":"Liu, C. C. et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron 96, 1024\u20131032.e3 (2017).","journal-title":"Neuron"},{"key":"1171_CR7","doi-asserted-by":"publisher","first-page":"332ra44","DOI":"10.1126\/scitranslmed.aad3650","volume":"8","author":"CC Liu","year":"2016","unstructured":"Liu, C. C. et al. Neuronal heparan sulfates promote amyloid pathology by modulating brain amyloid-beta clearance and aggregation in Alzheimer\u2019s disease. Sci. Transl. Med. 8, 332ra44 (2016).","journal-title":"Sci. Transl. Med."},{"key":"1171_CR8","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.1038\/s43587-023-00490-2","volume":"3","author":"JP Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza, J. P. et al. APOE\u03b54 potentiates amyloid beta effects on longitudinal tau pathology. Nat. Aging 3, 1210\u20131218 (2023).","journal-title":"Nat. Aging"},{"key":"1171_CR9","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature24016","volume":"549","author":"Y Shi","year":"2017","unstructured":"Shi, Y. et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature 549, 523\u2013527 (2017).","journal-title":"Nature"},{"key":"1171_CR10","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault, J. et al. Association of apolipoprotein E \u03b54 with medial temporal tau independent of amyloid-beta. JAMA Neurol. 77, 470\u2013479 (2020).","journal-title":"JAMA Neurol."},{"key":"1171_CR11","doi-asserted-by":"publisher","first-page":"101594","DOI":"10.1016\/j.smim.2022.101594","volume":"59","author":"S Parhizkar","year":"2022","unstructured":"Parhizkar, S. & Holtzman, D. M. APOE mediated neuroinflammation and neurodegeneration in Alzheimer\u2019s disease. Semin. Immunol. 59, 101594 (2022).","journal-title":"Semin. Immunol."},{"key":"1171_CR12","doi-asserted-by":"publisher","first-page":"eade1474","DOI":"10.1126\/sciadv.ade1474","volume":"9","author":"JP Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza, J. P. et al. APOE \u03b54 associates with microglial activation independently of A\u03b2 plaques and tau tangles. Sci. Adv. 9, eade1474 (2023).","journal-title":"Sci. Adv."},{"key":"1171_CR13","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.it.2016.06.006","volume":"37","author":"E Colombo","year":"2016","unstructured":"Colombo, E. & Farina, C. Astrocytes: key regulators of neuroinflammation. Trends Immunol. 37, 608\u2013620 (2016).","journal-title":"Trends Immunol."},{"key":"1171_CR14","doi-asserted-by":"publisher","first-page":"3385","DOI":"10.12998\/wjcc.v11.i15.3385","volume":"11","author":"L Gradisnik","year":"2023","unstructured":"Gradisnik, L. & Velnar, T. Astrocytes in the central nervous system and their functions in health and disease: a review. World J. Clin. Cases 11, 3385\u20133394 (2023).","journal-title":"World J. Clin. Cases"},{"key":"1171_CR15","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon, H. S. & Koh, S. H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl. Neurodegener. 9, 42 (2020).","journal-title":"Transl. Neurodegener."},{"key":"1171_CR16","first-page":"1005","volume":"12","author":"T Wyss-Coray","year":"2006","unstructured":"Wyss-Coray, T. Inflammation in Alzheimer disease: driving force, bystander or beneficial response? Nat. Med. 12, 1005\u20131015 (2006).","journal-title":"Nat. Med."},{"key":"1171_CR17","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S0896-6273(02)00794-8","volume":"35","author":"T Wyss-Coray","year":"2002","unstructured":"Wyss-Coray, T. & Mucke, L. Inflammation in neurodegenerative disease\u2014a double-edged sword. Neuron 35, 419\u2013432 (2002).","journal-title":"Neuron"},{"key":"1171_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1038\/s41593-020-00783-4","volume":"24","author":"C Escartin","year":"2021","unstructured":"Escartin, C. et al. Reactive astrocyte nomenclature, definitions, and future directions. Nat. Neurosci. 24, 312\u2013325 (2021).","journal-title":"Nat. Neurosci."},{"key":"1171_CR19","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro, R. et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer\u2019s disease. Biol. Psychiatry 68, 903\u2013912 (2010).","journal-title":"Biol. Psychiatry"},{"key":"1171_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.2174\/1570159X15666170208124324","volume":"15","author":"P Muszynski","year":"2017","unstructured":"Muszynski, P. et al. YKL-40 as a potential biomarker and a possible target in therapeutic strategies of Alzheimer\u2019s disease. Curr. Neuropharmacol. 15, 906\u2013917 (2017).","journal-title":"Curr. Neuropharmacol."},{"key":"1171_CR21","doi-asserted-by":"crossref","unstructured":"Mavroudis, I. et al. YKL-40 as a potential biomarker for the differential diagnosis of Alzheimer\u2019s disease. Medicina 58, 60 (2021).","DOI":"10.3390\/medicina58010060"},{"key":"1171_CR22","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester, M. I. et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer\u2019s disease in a memory clinic cohort. Alzheimers Res. Ther. 7, 59 (2015).","journal-title":"Alzheimers Res. Ther."},{"key":"1171_CR23","doi-asserted-by":"publisher","first-page":"e2944","DOI":"10.1212\/WNL.0000000000012109","volume":"96","author":"B Bellaver","year":"2021","unstructured":"Bellaver, B. et al. Astrocyte biomarkers in Alzheimer disease: a systematic review and meta-analysis. Neurology 96, e2944\u2013e2955 (2021).","journal-title":"Neurology"},{"key":"1171_CR24","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/0005-2760(87)90295-5","volume":"917","author":"RE Pitas","year":"1987","unstructured":"Pitas, R. E. et al. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E-containing lipoproteins. Biochim. Biophys. Acta 917, 148\u2013161 (1987).","journal-title":"Biochim. Biophys. Acta"},{"key":"1171_CR25","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41583-023-00776-9","volume":"25","author":"J Blumenfeld","year":"2024","unstructured":"Blumenfeld, J. et al. Cell type-specific roles of APOE4 in Alzheimer disease. Nat. Rev. Neurosci. 25, 91\u2013110 (2024).","journal-title":"Nat. Rev. Neurosci."},{"key":"1171_CR26","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3389\/fnagi.2019.00014","volume":"11","author":"CG Fernandez","year":"2019","unstructured":"Fernandez, C. G. et al. The role of APOE4 in disrupting the homeostatic functions of astrocytes and microglia in aging and Alzheimer\u2019s disease. Front. Aging Neurosci. 11, 14 (2019).","journal-title":"Front. Aging Neurosci."},{"key":"1171_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1002\/glia.24469","volume":"72","author":"M Eisenbaum","year":"2024","unstructured":"Eisenbaum, M. et al. ApoE4 expression disrupts tau uptake, trafficking, and clearance in astrocytes. Glia 72, 184\u2013205 (2024).","journal-title":"Glia"},{"key":"1171_CR28","doi-asserted-by":"publisher","first-page":"4781","DOI":"10.1038\/s41380-022-01716-2","volume":"27","author":"JP Ferrari-Souza","year":"2022","unstructured":"Ferrari-Souza, J. P. et al. Astrocyte biomarker signatures of amyloid-beta and tau pathologies in Alzheimer\u2019s disease. Mol. Psychiatry 27, 4781\u20134789 (2022).","journal-title":"Mol. Psychiatry"},{"key":"1171_CR29","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann, G. M. et al. The diagnosis of dementia due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimers Dement. 7, 263\u2013269 (2011).","journal-title":"Alzheimers Dement."},{"key":"1171_CR30","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1001\/jamaneurol.2021.3671","volume":"78","author":"AL Benedet","year":"2021","unstructured":"Benedet, A. L. et al. Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum. JAMA Neurol. 78, 1471\u20131483 (2021).","journal-title":"JAMA Neurol."},{"key":"1171_CR31","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.exger.2019.04.003","volume":"121","author":"CS Jensen","year":"2019","unstructured":"Jensen, C. S. et al. Exercise as a potential modulator of inflammation in patients with Alzheimer\u2019s disease measured in cerebrospinal fluid and plasma. Exp. Gerontol. 121, 91\u201398 (2019).","journal-title":"Exp. Gerontol."},{"key":"1171_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.2174\/1381612828666220413094918","volume":"28","author":"AB Pomilio","year":"2022","unstructured":"Pomilio, A. B., Vitale, A. A. & Lazarowski, A. J. Neuroproteomics chip-based mass spectrometry and other techniques for Alzheimer\u2019s disease biomarkers\u2014update. Curr. Pharm. Des. 28, 1124\u20131151 (2022).","journal-title":"Curr. Pharm. Des."},{"key":"1171_CR33","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jalz.2016.08.005","volume":"13","author":"CR Jack Jr.","year":"2017","unstructured":"Jack, C. R. Jr. et al. Defining imaging biomarker cut points for brain aging and Alzheimer\u2019s disease. Alzheimers Dement. 13, 205\u2013216 (2017).","journal-title":"Alzheimers Dement."},{"key":"1171_CR34","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/BF00308809","volume":"82","author":"H Braak","year":"1991","unstructured":"Braak, H. & Braak, E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol. 82, 239\u2013259 (1991).","journal-title":"Acta Neuropathol."},{"key":"1171_CR35","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/S0197-4580(97)00056-0","volume":"18","author":"H Braak","year":"1997","unstructured":"Braak, H. & Braak, E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol. Aging 18, 351\u2013357 (1997).","journal-title":"Neurobiol. Aging"},{"key":"1171_CR36","doi-asserted-by":"publisher","first-page":"2818","DOI":"10.1093\/brain\/awaa180","volume":"143","author":"TA Pascoal","year":"2020","unstructured":"Pascoal, T. A. et al. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles. Brain 143, 2818\u20132830 (2020).","journal-title":"Brain"},{"key":"1171_CR37","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1016\/j.neuron.2016.01.028","volume":"89","author":"M Scholl","year":"2016","unstructured":"Scholl, M. et al. PET imaging of tau deposition in the aging human brain. Neuron 89, 971\u2013982 (2016).","journal-title":"Neuron"},{"key":"1171_CR38","unstructured":"Trudel, L. et al. Implication for clinical trials from longitudinal tau-PET accumulation across biological Alzheimer\u2019s disease stages. Neurology 105, e214111 (2025)."},{"key":"1171_CR39","doi-asserted-by":"crossref","unstructured":"Trudel, L., Macedo, T. J., Servaes, A. & Hosseini, S. S. A. Rates of clinical progression according to biological Alzheimer\u2019s disease stages. Alzheimers Dement. 21, e70624 (2025).","DOI":"10.1002\/alz.70624"},{"key":"1171_CR40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1038\/nature11405","volume":"489","author":"MJ Hawrylycz","year":"2012","unstructured":"Hawrylycz, M. J. et al. An anatomically comprehensive atlas of the adult human brain transcriptome. Nature 489, 391\u2013399 (2012).","journal-title":"Nature"},{"key":"1171_CR41","doi-asserted-by":"publisher","first-page":"D996","DOI":"10.1093\/nar\/gks1042","volume":"41","author":"SM Sunkin","year":"2013","unstructured":"Sunkin, S. M. et al. Allen Brain Atlas: an integrated spatio-temporal portal for exploring the central nervous system. Nucleic Acids Res. 41, D996\u2013D1008 (2013).","journal-title":"Nucleic Acids Res."},{"key":"1171_CR42","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.neuroimage.2018.04.068","volume":"176","author":"G Gryglewski","year":"2018","unstructured":"Gryglewski, G. et al. Spatial analysis and high resolution mapping of the human whole-brain transcriptome for integrative analysis in neuroimaging. Neuroimage 176, 259\u2013267 (2018).","journal-title":"Neuroimage"},{"key":"1171_CR43","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0022-2275(20)43176-1","volume":"31","author":"JE Hixson","year":"1990","unstructured":"Hixson, J. E. & Vernier, D. T. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. J. Lipid Res. 31, 545\u2013548 (1990).","journal-title":"J. Lipid Res."},{"key":"1171_CR44","doi-asserted-by":"publisher","first-page":"171","DOI":"10.3389\/fnins.2012.00171","volume":"6","author":"A Klein","year":"2012","unstructured":"Klein, A. & Tourville, J. 101 labeled brain images and a consistent human cortical labeling protocol. Front. Neurosci. 6, 171 (2012).","journal-title":"Front. Neurosci."},{"key":"1171_CR45","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci, F. et al. Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev. Proteomics 14, 285\u2013299 (2017).","journal-title":"Expert Rev. Proteomics"},{"key":"1171_CR46","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/acn3.266","volume":"3","author":"S Janelidze","year":"2016","unstructured":"Janelidze, S. et al. Cerebrospinal fluid neurogranin and YKL-40 as biomarkers of Alzheimer\u2019s disease. Ann. Clin. Transl. Neurol. 3, 12\u201320 (2016).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"1171_CR47","doi-asserted-by":"publisher","first-page":"725511","DOI":"10.3389\/fpsyt.2021.725511","volume":"12","author":"K Wilczynska","year":"2021","unstructured":"Wilczynska, K. et al. Serum amyloid biomarkers, tau protein and YKL-40 utility in detection, differential diagnosing, and monitoring of dementia. Front. Psychiatry 12, 725511 (2021).","journal-title":"Front. Psychiatry"},{"key":"1171_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/alz.13450","volume":"20","author":"W Pelkmans","year":"2024","unstructured":"Pelkmans, W. et al. Astrocyte biomarkers GFAP and YKL-40 mediate early Alzheimer\u2019s disease progression. Alzheimers Dement. 20, 483\u2013493 (2024).","journal-title":"Alzheimers Dement."},{"key":"1171_CR49","doi-asserted-by":"publisher","first-page":"113183","DOI":"10.1016\/j.celrep.2023.113183","volume":"42","author":"H Lee","year":"2023","unstructured":"Lee, H. et al. ApoE4-dependent lysosomal cholesterol accumulation impairs mitochondrial homeostasis and oxidative phosphorylation in human astrocytes. Cell Rep. 42, 113183 (2023).","journal-title":"Cell Rep."},{"key":"1171_CR50","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1016\/j.neuron.2023.10.023","volume":"112","author":"A Litvinchuk","year":"2024","unstructured":"Litvinchuk, A. et al. Amelioration of Tau and ApoE4-linked glial lipid accumulation and neurodegeneration with an LXR agonist. Neuron 112, 384\u2013403.e8 (2024).","journal-title":"Neuron"},{"key":"1171_CR51","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/s43587-023-00368-3","volume":"3","author":"N Koutsodendris","year":"2023","unstructured":"Koutsodendris, N. et al. Neuronal APOE4 removal protects against tau-mediated gliosis, neurodegeneration and myelin deficits. Nat. Aging 3, 275\u2013296 (2023).","journal-title":"Nat. Aging"},{"key":"1171_CR52","doi-asserted-by":"publisher","first-page":"e867","DOI":"10.1212\/WNL.0000000000006082","volume":"91","author":"S Janelidze","year":"2018","unstructured":"Janelidze, S. et al. CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer disease. Neurology 91, e867\u2013e877 (2018).","journal-title":"Neurology"},{"key":"1171_CR53","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1038\/s41591-023-02476-4","volume":"29","author":"ECB Johnson","year":"2023","unstructured":"Johnson, E. C. B. et al. Cerebrospinal fluid proteomics define the natural history of autosomal dominant Alzheimer\u2019s disease. Nat. Med. 29, 1979\u20131988 (2023).","journal-title":"Nat. Med."},{"key":"1171_CR54","doi-asserted-by":"publisher","first-page":"107394","DOI":"10.1016\/j.pharmthera.2019.107394","volume":"203","author":"IJ Yeo","year":"2019","unstructured":"Yeo, I. J. et al. Roles of chitinase 3-like 1 in the development of cancer, neurodegenerative diseases, and inflammatory diseases. Pharm. Ther. 203, 107394 (2019).","journal-title":"Pharm. Ther."},{"key":"1171_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s12883-016-0742-9","volume":"16","author":"Y Deming","year":"2016","unstructured":"Deming, Y. et al. Chitinase-3-like 1 protein (CHI3L1) locus influences cerebrospinal fluid levels of YKL-40. BMC Neurol. 16, 217 (2016).","journal-title":"BMC Neurol."},{"key":"1171_CR56","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.molmed.2018.11.006","volume":"25","author":"SF Carter","year":"2019","unstructured":"Carter, S. F. et al. Astrocyte biomarkers in Alzheimer\u2019s disease. Trends Mol. Med. 25, 77\u201395 (2019).","journal-title":"Trends Mol. Med."}],"container-title":["Communications Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01171-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01171-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T14:03:33Z","timestamp":1763647413000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43856-025-01171-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1171"],"URL":"https:\/\/doi.org\/10.1038\/s43856-025-01171-4","relation":{},"ISSN":["2730-664X"],"issn-type":[{"value":"2730-664X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]},"assertion":[{"value":"10 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.T. has served as a consultant for the Neurotorium Educational Platform and as a medical writer for Alzheon Inc., both outside of the scope of the present work. P.V. serves on the scientific advisory boards for NovoNordisc, Eisai, and Lilly, and received honoraria from IntelGenx Corp. S.G. is a member of the scientific advisory boards of AbbVie, Alzheon, AmyriAD, Eisai Canada, Enigma USA, Lilly Canada, Novo Nordisk Canada, TauRx. T.C. has served on the scientific advisory board of Eisai outside the scope of the present work. T.K.K. has consulted for Quanterix Corporation, SpearBio Inc., Neurogen Biomarking LLC., and Alzheon, and has served on advisory boards for Siemens Healthineers and Neurogen Biomarking LLC., outside the submitted work. He has received in-kind research support from Janssen Research Laboratories, SpearBio Inc., and Alamar Biosciences, as well as meeting travel support from the Alzheimer\u2019s Association and Neurogen Biomarking LLC., outside the submitted work. T.K.K. has received royalties from Bioventix for the transfer of specific antibodies and assays to third-party organizations. He has received honoraria for speaker\/grant review engagements from the NIH, UPENN, UW-Madison, the Cherry Blossom symposium, the HABS-HD\/ADNI4 Health Enhancement Scientific Program, Advent Health Translational Research Institute, Brain Health conference, Barcelona-Pittsburgh conference, the International Neuropsychological Society, the Icahn School of Medicine at Mount Sinai and the Quebec Center for Drug Discovery, Canada, all outside of the submitted work. T.K.K. is an inventor on several patents and provisional patents regarding biofluid biomarker methods, targets and reagents\/compositions, that may generate income for the institution and\/or self should they be licensed and\/or transferred to another organization. These include WO2020193500A1: Use of a ps396 assay to diagnose tauopathies; US 63\/679,361: Methods to Evaluate Early-Stage Pre-Tangle TAU Aggregates and Treatment of Alzheimer\u2019s Disease Patients; US 63\/672,952: Method for the Quantification of Plasma Amyloid-Beta Biomarkers in Alzheimer\u2019s Disease; US 63\/693,956: Anti-tau Protein Antigen Binding Reagents; and 2450702-2: Detection of oligomeric tau and soluble tau aggregates. N.J.A. has given lectures in symposia sponsored by Eli-Lilly, Roche Diagnostics, Alamar Biosciences, Biogen, VJDementia and Quanterix; consulted for Quanterix, TauRx, Neurogen Biomarking; served on advisory boards for Biogen, TauRx, and TargetALS; and has a pending patent application (PCT\/US2024\/037834 (WSGR Docket No. 58484-709.601): Methods for Remote Blood Collection, Extraction and Analysis of Neuro Biomarkers). E.R.Z. has served on the scientific advisory board, as a consultant or speaker for Nintx, Novo Nordisk, Biogen, Lilly and Magdalena Biosciences. He is also a co-founder and minority shareholder of Masima. H.Z. has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of CERimmune Therapeutics (outside submitted work). K.B. has served as a consultant and on advisory boards for AbbVie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. P.R.-N. has served on scientific advisory boards and\/or as a consultant for Roche, Novo Nordisk, Eisai and Cerveau Technologies, outside of the scope of the present work. All other authors (L.T., A.C.M., N.R., E.A., S.S., S.A.H., J.P.F.-Z., B.B., P.L.F., Y.-T.W., J.F.-A., Y.Z., B.H., J.S., R.H., C.H.H., M.M., J.K. and T.A.P.) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"484"}}